[G22-37] Enfortumab vedotin (urothelial cancer) – 2nd addendum to commission A22-61
Last updated 15.12.2022
Project no.:
G22-37
Commission:
Commission awarded on 11.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Health Economics
Topic:
Cancer
Note:
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
| Project no. | Title | Status |
|---|---|---|
| A22-61 | Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.
G-BA documents on this decision